Sentinel lymph node evaluation does not improve staging accuracy in colon cancer

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 46-51

  Lim, Sherry J ^a   Feig, Barry W ^a   Wang, Huamin ^a   Hunt, Kelly K ^a   Rodriguez Bigas, Miguel A ^a   Skibber, John M ^a   Ellis, Vickie ^a   Cleary, Karen ^a   Chang, George J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Colon cancer; Immunohistochemistry; Sentinel lymph node; Staging

Indexed keywords

EOSIN; HEMATOXYLIN; ISOSULFAN BLUE; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LABORATORY DIAGNOSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; ROSANILINE DYES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 38049175140     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9629-8     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:106-30
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51
4. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-806
5. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70
6. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8
7. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998;339:941-6
8. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999;91:368-73
9. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006;24:4464-71
10. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17
11. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9
12. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006;13:927-32
13. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99:414-5
14. Jestin P, Pahlman L, Glimelius B, Gunnarsson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer 2005;41:2071-8
15. Suzuki O, Sekishita Y, Shiono T, et al. Number of lymph node metastases is better predictor of prognosis than level of lymph node metastasis in patients with node-positive colon cancer. J Am Coll Surg 2006;202:732-6
16. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003;10:65-71
17. Feig BW, Curley S, Lucci A, et al. A caution regarding lymphatic mapping in patients with colon cancer. Am J Surg 2001;182:707-12
18. Patten LC, Berger DH, Rodriguez-Bigas M, et al. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping. Cancer 2004;100:2104-9
19. Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004;240:624-8
20. Bilchik AJ, DiNome M, Saha S, et al. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 2006;141:527-33
21. Saha S, Seghal R, Patel M, et al. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 2006;191:305-10
22. Des Guetz GN, Wind P, Breau P, et al. Is sentinel lymph node mapping in colorectal cancer a future prognostic factor? Meta-analysis of the literature. In: Grunberg SM, ed. Gastrointestinal Cancer Symposium. Orlando, FL: American Society of Clinical Oncology, 2007:288
23. Redston M, Compton CC, Miedema BW, et al. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 2006;24:878-83
24. Broll R, Schauer V, Schimmelpenning H, et al. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas: an immunohistochemical study. Dis Colon Rectum 1997;40:1465-71
25. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-9
26. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 2006;13:1386-92